Thrombophilia in infancy: Factor V Leiden and MTHFR or factor II double heterozygocity as a risk factor

Pediatric Hematology and Oncology

Volumn 20, Issue 3, 2003, Pages 219-227

  Koren, Ariel ^a,b   Levin, Carina ^a   Hujirat, Yaser ^a   El Hasid, Ronit ^c   Kutai, Miriam ^a   Lanir, Naomi ^c   Shalev, Stavit ^a   Brenner, Benjamin ^b,c  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Genetic factors; Infants; Newborns; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ARTICLE; BRAIN INFARCTION; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ETHNIC GROUP; FEMALE; GENE MUTATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; INFANT DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEWBORN; PRENATAL DIAGNOSIS; THROMBOPHILIA;

EID: 0037393505     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390158847     Document Type: Article

References (28)

1. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74:415-425.
2. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90:1-11.
3. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;10:3562-3565.
4. McColl MD, Chalmers EA, Thomas A, et al. Factor V Leiden, prothrombin 20210 G → A and the MTHFR C677T mutations in childhood storoke. Thromb Haemost. 1999;81:690-694.
5. Zenz W, Bodo Z, Plotho J, et al. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost. 1998;80:763-766.
6. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke. 2000;31:1283-1288.
7. Nowak-Gottl U, Strater R, Heinecke A, Koch HG, Schuierer G, von Eckardstein A. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94:3678-3682.
8. Heller C, Schobess R, Kurnik K, et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. Br J Haematol. 2000;111:534-539.
9. Gunther G, Junker R, Strater R, et al. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke. 2000;31:2437-2441.
10. Dizon-Townson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol. 1997;176:883-886.
11. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet. 1995;10:111-113.
13. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE. Blood. 1994;83:1251-1257.
14. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics. 1995;96:939-943.
15. Ehrenforth S, Junker R, Koch HG, et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood: childhood thrombophilia study group. Eur J Pediatr. 1999;158(Suppl 3):S97-S104.
16. Strater R, Vielhaber H, Kassenbohmer R, von-Kries R, Gobel U, Nowak-Gottl U. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin: a prospective ESPED survey. Eur J Pediatr. 1999;158(Suppl 3):S122-S125.
17. Junker R, Koch HG, Auberger K, Munchow N, Ehrenforth S, Nowak-Gottl U. Arterioscler Thromb Vasc Biol. 1999;19:2568-2572.
18. Vielhaber H, Ehrenforth S, Koch HG, Scharrer I, van der Werf N, Nowak-Gottl U. Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and aquired risk factors of thrombophilia. Eur J Pediatr. 1998;157:555-560.
19. Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single center. Arch Dis Child. 1999;81:176-178.
20. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden: effect on thrombosis. N Engl J Med. 1996;334:763-768.
21. Becker S, Heller Ch, Gropp F, Scharrer I, Kreuz W. Thrombophilic disorders in children with cerebral infarction. Lancet. 1998;352:1756-1757.
22. Mercuri E, Cowan F, Gupte G, et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics. 2001;107:1400-1404.
23. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Arterioscler Thromb Vasc Biol. 1999;19:511-518.
24. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995;85:607-614.
25. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
26. Rodgers GM, Cohn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901.
27. Nowak-Gottl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97:858-862.
28. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 2001;119: 344S-370S.